Key result
Low-molecular-weight heparins are effective and safe for preventing and treating venous thromboembolism, including in outpatient settings and high-risk surgical patients.
Why the study?
Do low-molecular-weight heparins improve the prevention and treatment of venous thromboembolism compared to unfractionated heparin or placebo in high-risk patients?
Population
Patients at risk for or with venous thromboembolism, including high-risk surgical patients, high-risk…
Comparison
Low-molecular-weight heparins (LMWHs) vs Unfractionated heparin or placebo
Design
Review
Authors
Loading...
May support outpatient LMWH use for VTE; extends prior reviews but leaves open need for updated RCTs in contemporary cohorts.
Do low-molecular-weight heparins improve the prevention and treatment of venous thromboembolism compared to unfractionated heparin or placebo in high-risk patients?
Low-molecular-weight heparins provide an effective and safe alternative to unfractionated heparin for VTE prevention and treatment, enabling outpatient management and extended post-discharge prophylaxis.
Graham F. Pineo (2001) conducted a review in Venous thromboembolism. Low-molecular-weight heparins (LMWHs) vs. Unfractionated heparin and placebo was evaluated. Low-molecular-weight heparins are effective and safe for preventing and treating venous thromboembolism, including in outpatient settings and high-risk surgical patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: